XML 35 R85.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Additional Information (Detail)
£ in Millions
6 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2017
Jun. 30, 2017
USD ($)
Dec. 31, 2019
GBP (£)
Statutory federal corporate income tax rate 21.00% 21.00% 27.50%   34.00%    
Changes in valuation allowance $ 7,166,000 $ 15,608,000   $ (5,385,000)   $ 7,489,000  
Change in valuation allowance due to impact of 2017 Tax Act       765,000      
Unrecognized tax benefits   0          
Accrued penalties or interest related to uncertain tax positions $ 0 0 $ 0        
U.S. Federal [Member]              
Operating loss carry forwards   236,600,000          
Net operating loss carry forwards   $ 151,800,000          
Operating loss carry forwards, expiration range start dates   2023          
Operating loss carry forwards, expiration range end dates   2038          
Tax years that remain subject to examination   2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017          
State [Member]              
Operating loss carry forwards   $ 190,100,000          
United Kingdom Tax Authority [Member]              
Operating loss carry forwards   $ 26,700,000         £ 21.0
Tax years that remain subject to examination   2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017          
Federal and State Research and Development Tax Credit Carryforward [Member]              
Research and development tax credit carry forwards   $ 3,100,000          
Federal And State Tax [Member]              
Research and development tax credit carry forwards expiration begin date   2018          
Research and development tax credit carry forwards expiration end date   2038          
Icon Bioscience Inc [Member]              
Deferred tax asset       $ 6,200,000      
Icon Bioscience Inc [Member] | U.S. Federal [Member]              
Operating loss carry forwards   $ 49,300,000